Philip Robert Corlett
Associate Professor of Psychiatry at Yale School of Medicine
Data updated
Research Footprint
Philip Robert Corlett appears in 6 tracked papers (2010–2024), most studied alongside Ketamine and Psilocybin, across Neuroimaging & Brain Measures, Depressive Disorders and Schizophrenia.
Most-cited paper: Glutamatergic Model Psychoses: Prediction Error, Learning, and Inference (237 citations).
Frequent co-authors: John Krystal, Katrin Preller and Christopher Timmermann.
Background & Research
Dr. Philip Robert Corlett is an Associate Professor of Psychiatry at Yale School of Medicine and a faculty member in the Department of Psychology. He trained in experimental psychology, cognitive neuroscience, and psychiatry at the University of Cambridge, where he completed his PhD on the brain bases of delusion formation before moving to Yale to study the maintenance of delusions and related belief processes. His work uses behavioral experiments, computational modeling, and neuroimaging to investigate how beliefs, inference, and perception break down in psychosis and under altered states, including psychedelics and ketamine.
Key Impact
He is a leading Yale researcher on delusions, hallucinations, predictive processing, and the psychotomimetic effects of ketamine and psychedelics, with multiple papers directly relevant to psychedelic science.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Philip Robert Corlett is associated with.
VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →University of Cambridge
academicThe Cambridge Psychedelic Research Group (CPRG) brings together scientists, psychiatrists, and clinical psychologists to rigorously advance psychedelic-assisted therapy for mental health. The CPRG initiated its first clinical trials focusing on psychedelic-assisted therapy for post-traumatic stress disorder (PTSD). Currently, the center is initiating additional trials to investigate the therapeutic potential of psilocybin for adults suffering from treatment-resistant depression and generalized anxiety disorder.
View stakeholder →